Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Jun 8;7(2):5812.
doi: 10.4081/hr.2015.5812. eCollection 2015 Jun 3.

Favorable Event Free-Survival of High-Dose Chemotherapy Followed by Autologous Hematopoietic Stem Cell Transplantation for Higher Risk Diffuse Large B-Cell Lymphoma in First Complete Remission

Hiroto Kaneko  1 , Yasuhiko Tsutsumi  1 , Takahiro Fujino  1 , Saeko Kuwahara  1 , Muneo Ohshiro  1 , Toshiki Iwai  1 , Junya Kuroda  2 , Shouhei Yokota  2 , Shigeo Horiike  2 , Masafumi Taniwaki  2
Affiliations

Favorable Event Free-Survival of High-Dose Chemotherapy Followed by Autologous Hematopoietic Stem Cell Transplantation for Higher Risk Diffuse Large B-Cell Lymphoma in First Complete Remission

Hiroto Kaneko et al. Hematol Rep. .

Abstract

High-dose chemotherapy followed by autologous stem cell transplantation (ASCT) has been applied to patients with diffuse large Bcell lymphoma (DLBCL); it is well established that ASCT shows significant survival benefits for chemosensitive relapse. However, half of relapsed patients are resistant to salvage chemotherapy, indicating that they are not suitable for ASCT. We retrospectively analyzed the clinical records of 47 patients with DLBCL classified as high or high-intermediate (higher) risk, according to the International Prognostic Index, who underwent upfront ASCT in first complete remission (CR1). Compared with 10 patients with similar characteristics who did not receive ASCT, event free survival at 5-year was significantly superior in ASCT group. Toxicity of ASCT was acceptable and therapy-related death was not observed. We therefore propose that upfront ASCT for higher risk DLBCL in CR1 might provide survival benefit, probably because the high-dose therapy removes minimally resided tumor.

Keywords: Diffuse large B-cell lymphoma; autologous transplantation; upfront.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: the authors declare no potential conflict of interest.

Figures

Figure 1.
Figure 1.
Event free survival of patients with autologous stem cell transplantation (ASCT) compared to those without ASCT. Significant superiority by log-rank test in patients with ASCT is observed (75.8% vs 45%).
See this image and copyright information in PMC

References

    1. Vaidya R, Witzig TE. Prognostic factors for diffuse large B-cell lymphoma in the R(x)CHOP era. Ann Oncol 2014;25:2124-33. - PMC - PubMed
    1. The International Non-Hodgkin’s Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin’s lymphoma. N Engl J Med 1993;329:987-94. - PubMed
    1. The Non-Hodgkin’s Lymphoma Classification Project. Effect of age on the characteristics and clinical behavior of non-Hodgkin’s lymphoma patients. Ann Oncol 1997;8:973-8. - PubMed
    1. Verdonck LF, van Putten WL, Hagenbeek A, et al. Comparison of CHOP chemotherapy with autologous bone marrow transplantation for slowly responding patients with aggressive non-Hodgkin’s lymphoma. N Engl J Med 1995;332:1045-51. - PubMed
    1. Martelli M, Vignetti M, Zinzani PL, et al. High-dose chemotherapy followed by autologous bone marrow versus dexamethasone, cisplatin and cytarabine in aggressive non-Hodgkin’s lymphoma with partial response to front-line chemotherapy: a retrospective randomized Italian multicenter study. J Clin Oncol 1996;14:534-42. - PubMed

LinkOut - more resources